Reshape Lifesciences Stock (NASDAQ: RSLS)

Reshape Lifesciences Stock (NASDAQ:RSLS), Trade Ideas

Reshape Lifesciences

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Earnings

News

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BLBX

CCCC

LPTV

PCSA

RSLS

STTK

U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision on Wednesday.

The Dow traded up 0.58% to 36,789.77 while the NASDAQ rose 0.63% to 14,624.74. The S&amp;P 500 also rose, gaining, 0.62% to 4,672.48.

Dow Jumps Over 200 Points; Federal Reserve Holds Interest Rates Steady

Small Cap

Movers

CALM

DESP

EOSE

INAB

IOAC

IPDN

JBLU

MYNA

NEPH

NXTP

PLAB

REVG

SPRC

SVMH

TCBP

TTWO

VRTX

WHLR

WLGS

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance.

The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, following the release of PPI data on Wednesday.

The Dow traded up 0.06% to 36,598.24 while the NASDAQ rose 0.23% to 14,566.43. The S&amp;P 500 also rose, gaining, 0.20% to 4,653.07.

Crude Oil Gains 1.5%; Blackboxstocks Shares Plummet

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences Inc

SMFL

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

As 4/20 is upons us, <a href="https://www.benzinga.com/topic/weedmaps">Weedmaps </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) has provided valuable insights to forecast a significant sales boost for the industry and a widespread celebration of marijuana. The data, derived from big data analysis of user activities on the platform, indicates that the previous year&#8217;s 4/20 was highly successful, with Weedmaps experiencing a twofold increase in normal operations.
<h2 class="wp-block-heading">Big Data, Big Deals</h2>
Weedmaps pointed out that consumers are prioritizing value, as the platform registered a 200% surge in orders that redeem deals through the platform during 4/20 week of 2023 compared to 2022.&nbsp;
Furthermore, the platform has observed a rising trend in usage, with deal claims increasing by 100% over 2022. This uptick is likely motivated by price reductions, as the costs for flowers, vape pens, and edibles have continued to decrease for the second consecutive year, showing declines of 15%, 14%, and 17% when compared to 2021.
Weemaps also shared that consumers will probably be expending even more in goods than years before, since the average order value surged to $96.22 in 2023, a 14% increase compared to an average Thursday in April of 2023. This is despite deflation.
Additionally, the quantity of orders expanded by an average of 25% in terms of items per basket on 4/20 of last year, in comparison to 2022.
<h2 class="wp-block-heading">Category Insights</h2>
<ul>
<li>During the 4/20 retail week of 2023, vape pens witnessed a 29% growth over 2022, and an impressive 126% increase compared to 2020, with the largest demographic being Gen Z (31%).</li>
</ul>
<ul>
<li>Edibles are predominantly favored by consumers aged 50 and above, accounting for nearly half of all edible sales. The edibles category saw a 36% rise in orders during the 4/20 week of 2023 compared to the previous year.</li>
</ul>
<ul>
<li>Cannabis flower remains the top choice across all age groups, with nearly half of all orders on 4/20 in 2023 falling into this category. Remarkably, sales of flowers through Weedmaps surged by 47% on 4/20 compared to the prior year, and this growth expanded to 202% when compared to 4/20 in 2020.</li>
</ul>

Cannabis

MAPS

Unparalleled 4/20: Weedmaps Unveils Consumer Trends Ahead Of Cannabis Industry's Biggest Holiday

As you may have heard, cannabis consumption among older folks is on the rise. More specifically, seniors are one of the fastest-growing groups of <a href="https://www.benzinga.com/cannabis">cannabis users in the U.S. </a>
As it turns out, many older adults have been consuming weed for decades and new ones are joining in on the fun. Cannabis consumption among our parents and grandparents has quadrupled in the past eight years.
Study after study suggests that older adults are using cannabis to remedy an array of conditions such as sleep issues, pain,&nbsp;inflammation and to activate their appetites. 
But most consume because they still enjoy getting high.
"Sure, I sleep better with cannabis and topical creams alleviate my knee pain, but that's all new. I've been smoking pot for the past four decades and I see no reason to stop getting high," said Cynthia P who recently retired as an ER nurse in Ohio where recreational marijuana <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">became legal</a> last November.
Scientists and researchers are wisely becoming interested in this Baby Boomer demographic of 77 million, many of whom are healthy, economically stable and have no plans of checking out anytime soon, so they say.
One particular<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.804890/full" target="_blank" rel="noreferrer noopener">&nbsp;study</a>,&nbsp;that examined marijuana use in adults aged&nbsp;60 to 88 found that&nbsp;whole-plant cannabis did&nbsp;not harm&nbsp;cognition but rather the opposite.&nbsp;Older cannabis users, relative to non-users, had&nbsp;significantly greater neuronal communication between the cerebellum and hippocampus.
Why? Age-related changes in the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy" target="_blank" rel="noreferrer noopener">endocannabinoid system</a>&nbsp;(ECS) include a decrease in the number of cannabinoid receptors throughout the brain.&nbsp;The ECS,&nbsp;a significant aspect of our human physiology that&nbsp;helps maintain homeostasis,&nbsp;is a complex cell-signaling system in the brain and body that interacts with just about all of our&nbsp;other body systems.&nbsp;
Which means? During normal aging, the decline in cannabinoid receptors correlates with increased levels of inflammation in these brain regions causing a loss of neurons in the hippocampus, which is critical for learning and&nbsp;memory.&nbsp;This, in short, explains age-related memory impairment.&nbsp;&nbsp;
"Oh, I believe that," Cynthia told Benzinga. "While I never consumed for a full shift before going to work, I'm convinced that marijuana has helped keep me and my mind sharp as I aged. I'm not saying it's for everyone, but for people of my generation there's nothing better."
Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/04/38341776/hemp-space-grew-3x-the-rate-of-cannabis-where-did-marijuana-get-it-wrong">Hemp Space Grew 3X The Rate Of Cannabis, Where Did Marijuana Get It Wrong?</a>
Photo: Shutterstock

Exclusives

It's 4/20, Do You Know Where Your Parents Are?

The Detroit Lions finished with one of their best records in years for the 2023 season, which means they will have a lower pick in the<a href="https://www.benzinga.com/nfldraft/"> 2024 NFL Draft.</a>
Would General Manager Brad Holmes consider trading out of the first round with the 2024 NFL Draft taking place in Detroit?
What Happened: Detroit Lions fans might not like the answer given by Holmes to the media on scenarios that could see the Lions trade their 29th overall first-round pick and move back in the <a href="https://www.benzinga.com/nfldraft/detroit-live-events/">2024 NFL Draft.</a>
Holmes was asked about a scenario of trading out of the first round and didn't hesitate to say he will do what is best for the franchise.
"We have to do the right thing for the organization," Holmes said, as <a href="https://www.detroitlions.com/news/holmes-prepared-to-apologize-to-fans-if-lions-trade-out-of-first-round">reported </a>by Lions writer Mike O'Hara.
Holmes said while he would consider trading out of the first round, it's important to note that, with the draft taking place in Detroit, there might be a greater chance of upsetting the fans if he makes such a move.
A trade out of the first round could mean that any Lions fans in attendance Thursday will have spent all day downtown to watch other teams take their players in the draft.
Holmes said he would send out a "PSA and apologize" if he trades out of the first round.
"Hopefully, our fans will forgive us. We won't expect immediate forgiveness right then and there, but hopefully when the season starts."
Detroit was announced as the host city for the NFL Draft back in 2022.
"Another opportunity for our franchise and our city and just for the world to kind of migrate to downtown Detroit," Holmes said earlier this week.
Related Link: <a href="https://www.benzinga.com/general/sports-betting/24/04/38318190/michigan-wolverines-will-have-6-high-demand-players-in-2024-nfl-draft-will-history-repeat-">Michigan Wolverines Will Have 6 High-Demand Players In 2024 NFL Draft: Will History Repeat Itself?</a>
Why It's Important: Holmes is no stranger to trading in the NFL Draft. Since joining as the Lions GM in 2021, Holmes has taken part in several drafts for the team and is known for dealmaking.
This includes the 2023 NFL Draft, which saw the Lions trade their sixth overall pick, acquired from the Los Angeles Rams in the Matthew Stafford trade. The Lions traded the sixth pick to the Arizona Cardinals and received back the 12th, 34th and 168th overall picks.
Lions fans will remember the 2023 Draft saw several impact players taken including running back Jahymyr Gibbs with the 12th pick and tight end Sam LaPorta with the 34th pick. Both rookies played in the 2023 NFL season and were among the top first-year players, finishing third and fourth, respectively, in NFC offensive rookie of the year voting.
The 12-5 record and appearance in the NFC Championship game gives the Lions the 29th overall pick, one of their lowest earned in years.
The Lions also have the 61st overall pick and 73rd, but have only those three picks in the first four rounds, with no fourth-round pick this year. This could prompt Holmes to be open to trades to pick up additional picks. The Lions also have a fifth-round pick, two sixth-round picks and a seventh-round pick, for seven overall picks.
In the 2023 NFL Draft, the Lions had eight picks, including two first-round picks and two second-round picks.
The Lions have had a first round pick in every season since 1994, with 1993 being the last year they didn't select a player in the first round.
The Lions&#8217; top needs by position include cornerback, offensive line and wide receiver. The Lions last took a wide receiver in the first round of 2022 (Jameson Williams) and a cornerback in the first round of 2020 (Jeff Okudah). For the offensive line, the Lions last took a guard or center in the first round in 2018 with Frank Ragnow, and last took an offensive tackle in the first round in 2021 with Penei Sewell. Of these four players, three are still with the Lions.
Join Benzinga's live draft reaction show Thursday, April 25 to hear our instant thought on who the Lions take 29th overall or our reaction to the Lions trading out of the first round.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; LIVE NFL Draft Watch Party: Benzinga&#039;s Expert Analysis &amp; Reactions!" width="500" height="281" src="https://www.youtube.com/embed/XMBqIWZb7h0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo via Shutterstock.

Sports

Detroit Lions Have First-Round Pick Every Year Since 1994: Would They Really Trade Out With Draft In Motor City?

&quot;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints,&quot; said John Brancaccio, Executive Chairman of Hepion. &quot;The Company remains committed to its strategic alternative efforts previously announced in December 2023. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner. There were no safety concerns observed for rencofilstat in the ASCEND-NASH trial.&quot;

Biotech

General

HEPA

Hepion Pharmaceuticals Says Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"

Hepion Pharmaceuticals Shares Resumed Trading

Sen. Elizabeth Warren (D-Mass.) voiced her support for a Department of Justice antitrust case against leading technology company Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which was <a href="https://www.benzinga.com/news/24/03/37905532/apple-slams-dangerous-doj-lawsuit-tim-cooks-iphone-suggestion-returns-to-haunt-and-potential-google">announced last month.</a>
In comments shared on social media, Warren took aim at the smartphone market segment of Apple.
What Happened: Apple is one of the largest smartphone companies in the world and in 2023 had seven of the top 10 selling smartphones globally <a href="https://www.benzinga.com/news/24/02/37245799/apple-dominates-2023-smartphone-list-with-7-of-top-10-models-why-its-important-for-iphone-growth">according to a report.</a>
According to Warren, Apple has a monopoly in the smartphone market and one of the company's key features could be ruining friendships and relationships.
"Green texts on iPhones, they're ruining relationships," Warren <a href="https://twitter.com/SenWarren/status/1781086997014040759">said </a>in a video posted on X.
The green texts refer to the texts that come from non-Apple phones in green bubbles versus the blue bubbles displayed by iPhone users.
"Non iPhone users everywhere are being excluded from group texts."
Warren said that this means some non-Apple smartphone users are not being included in chats about vacation plans, group chats or chats with other sports fans.
"And who's to blame here? Apple."
Warren said that the green vs. blue bubble text icons are just one example of the dirty tactics used by Apple to "keep a stranglehold on the smartphone market."
"Apple has used its monopoly on the smartphone to lock Americans into services and amass billions of dollars in profits."
Warren mentioned that apps that would let Google users use iMessage and get blue texts were <a href="https://www.benzinga.com/news/23/12/36165068/apple-pulls-plug-on-imessage-for-android-app-beeper-mini-its-back-to-green-bubbles-now-for-android-u">blocked by Apple.</a>
"It's time to break up Apple's monopoly now."
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37876155/apple-doj-lawsuit-could-challenge-core-business-model-leading-analyst-predicts-what">Apple DOJ Lawsuit Could Challenge &#8216;Core Business Model&#8217;: Leading Analyst Predicts What&#8217;s Next For Tech Giant</a>
Why It's Important: The video shared by Warren was Community Noted on X, with readers providing more context.
"As of Jan 2024, iPhone has a 57% market share, to Android 42% in North America. A monopoly is exclusive control, or no close substitutes," the note reads.
In March, the Department of Justice filed an antitrust suit against Apple, which includes allegations that the company restricts access to iPhone hardware and software features.
A <a href="https://9to5mac.com/2024/04/19/elizabeth-warren-on-green-texts/">report </a>from 9to5Mac indicates that the antitrust lawsuit now encompasses claims from non-iPhone users who feel socially stigmatized and excluded in chats with iPhone users. This issue stems from the ongoing<a href="https://www.benzinga.com/news/23/09/34818276/get-the-message-google-roasts-apple-with-new-mocking-ipager-add-to-end-green-vs-blue-text-bubbles-wa"> blue vs. green bubble text debate.</a>
AAPL Price Action: Apple shares closed at $165.00 on Friday, versus a 52-week trading range of $162.80 to $199.62.
Read Next:<a href="https://www.benzinga.com/general/politics/24/04/38305131/elizabeth-warren-says-trump-had-only-2-accomplishments-as-president-huge-difference-between-bide"> Elizabeth Warren Says Trump Had Only 2 Accomplishments As President: &#8216;Huge Difference Between&#8217; Biden, Trump</a>
Photo: Shutterstock

Politics

Legal

AAPL

Elizabeth Warren Attacks Apple Smartphone 'Monopoly': 'Green Texts On iPhones, They're Ruining Relationships'

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

Management

AFJK

On April 15, Aimei Health Technology's Juan Fernandez Pascual Tendered His Resignation As CEO, Secretary And A Director; Co Appointed Junheng Xie As CEO, Secretary And A Director

Honda Exec Says Company To Invest 4.2B Reais In Brazil Plant, Focusing On Hybrid-Flex Vehicles

COSM

Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules

BTOG

On Feb 19, Bit Origin Ltd Terminated Employment Of Its CFO, Xia Wang; On April 10, Lucas Wang Resigned As CEO And Chairman Of Board; Current COO, Has Been Appointed CEO, Chairman Of Board And A Director Of Co; Co To Conduct A Search To Replace Xia Wang As Company's CFO

Whales with a lot of money to spend have taken a noticeably bearish stance on ServiceNow.
Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 56 trades.
If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.
From the overall spotted trades, 25 are puts, for a total amount of $1,473,153 and 31, calls, for a total amount of $2,469,435.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1040.0 for ServiceNow over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $300.0 to $1040.0 in the last 30 days. 
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713559550_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$108.8</td>
<td>$106.7</td>
<td>$108.8</td>
<td>$700.00</td>
<td>$598.4K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$31.7</td>
<td>$36.5</td>
<td>$500.00</td>
<td>$310.2K</td>
<td style="text-align: right;">35</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$39.1</td>
<td>$36.7</td>
<td>$39.1</td>
<td>$700.00</td>
<td>$293.2K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$32.8</td>
<td>$32.1</td>
<td>$32.1</td>
<td>$720.00</td>
<td>$227.9K</td>
<td style="text-align: right;">75</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$33.0</td>
<td>$31.9</td>
<td>$33.0</td>
<td>$800.00</td>
<td>$132.0K</td>
<td style="text-align: right;">131</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About ServiceNow</h3>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Trading volume stands at 1,536,830, with NOW's price down by -2.39%, positioned at $713.91.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On ServiceNow

Financial giants have made a conspicuous bearish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 12 unusual trades.
Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,336, and 9 were calls, valued at $981,928.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $66.0 and $77.5 for AstraZeneca, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AstraZeneca's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AstraZeneca's whale activity within a strike price range from $66.0 to $77.5 in the last 30 days. 
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713559545_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.06</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$67.50</td>
<td>$594.6K</td>
<td>14.1K</td>
<td>8.2K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.65</td>
<td>$1.54</td>
<td>$1.55</td>
<td>$67.00</td>
<td>$69.4K</td>
<td>2.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$67.00</td>
<td>$67.6K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$1.49</td>
<td>$1.25</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$66.7K</td>
<td>2.5K</td>
<td>24</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.57</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$49.6K</td>
<td>2.5K</td>
<td>920</td>
</tr>
</tbody>
</table>

<h3>About AstraZeneca</h3>
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
Following our analysis of the options activities associated with AstraZeneca, we pivot to a closer look at the company's own performance.
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,720,283, the price of AZN is up by 0.28%, reaching $68.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Looking At AstraZeneca's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Astera Labs.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $55,500, and 8, calls, for a total amount of $413,781.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Astera Labs during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $35.0 to $100.0 in the last 30 days. 
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713559539_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$50.00</td>
<td>$73.5K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$30.9</td>
<td>$32.52</td>
<td>$35.00</td>
<td>$65.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$65.00</td>
<td>$63.8K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">89</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$65.00</td>
<td>$59.0K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">472</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$11.1</td>
<td>$10.7</td>
<td>$11.1</td>
<td>$75.00</td>
<td>$55.5K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.
Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Astera Labs</h3>
<ul>
<li>Trading volume stands at 3,996,863, with ALAB's price down by -10.18%, positioned at $63.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $88.0.
<ul>
<li>Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $100.</li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $85. </li>
<li>Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $85.</li>
<li>In a cautious move, an analyst from JP Morgan downgraded its rating to Overweight, setting a price target of $85. </li>
<li>Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Astera Labs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

GILD

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Offerings

KZIA

Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time

MNTS

Momentus Inc Receives Nasdaq Deficiency Notification Regarding Delayed Form 10-K

Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC. &nbsp;
The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the Nasdaq rules, the Company has 60 calendar days, or until June 17, 2024, to file the 2023 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until October 14, 2024, to regain compliance. If the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq.
The Company continues to work diligently to complete the 2023 Form 10-K and currently intends to file the 2023 Form 10-K by no later than June 10, 2024.
This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.

GURE

Gulf Resources Announces Receipt Of Nasdaq Non-Compliance Notice Notifying The Company That Due To The Co's Failure To Timely File Its Annual Report On Form 10-K For The Fiscal Year Ended December 31, 2023

Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the "Q3 Form 10-Q") and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the "Q1 Form 10-Q" and "Q2 Form 10-Q," respectively, and together with the Q3 Form 10-Q, the "Filings") with the Securities and Exchange Commission (the "SEC"), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company's continued listing on Nasdaq Global Select Market. &nbsp;
The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had previously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company's securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.
The Company continues to work diligently to complete the Filings and intends to file the Filings as promptly as possible to regain compliance under the Listing Rule. However, there can be no assurance that such periodic reports will be filed before the expiration of any stay granted by Nasdaq, or that the Nasdaq Hearing Panel will grant the Company's request for a further stay of any suspension or delisting action
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

LFCR

Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023

ReShape Lifesciences spikes as FDA clears new weight loss option

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we&rsquo;re starting the day with a breakdown of the biggest ones worth watching!



Moving stocks this morning are clinical trial news, an earnings report and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>RiskOn International (NASDAQ:<a href="https://investorplace.com/stock-quotes/roi-stock-quote/">ROI</a>) stock is rocketing more than 59% alongside insider buying.</li>



<li>Innovative International (NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) shares are soaring over 42% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317922105&amp;type=PDF&amp;symbol=IOACU&amp;cdn=8c06e942afe7500becaba0a1d26b274b&amp;companyName=Innovative+International+Acquisition+Corp.+Unit&amp;formType=DEFA14A&amp;formDescription=Additional+proxy+soliciting+materials+-+definitive&amp;dateFiled=2023-12-12">announcing a shareholder meeting date</a>.</li>



<li>Reshape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is surging more than 35% alongside <a href="https://www.nasdaq.com/press-release/reshape-lifesciencesr-receives-fda-pma-supplement-approval-for-its-next-generation">Food and Drug Administration (FDA) approval</a>.</li>



<li>Shattuck Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/sttk-stock-quote/">STTK</a>) shares are gaining over 24% with the <a href="https://www.nasdaq.com/press-release/shattuck-labs-announces-positive-initial-topline-data-from-ongoing-phase-1-a-b-dose">release of clinical trial data</a>.</li>



<li>Mynaric (NASDAQ:<a href="https://investorplace.com/stock-quotes/myna-stock-quote/">MYNA</a>) stock is increasing more than 16% after <a href="https://www.nasdaq.com/press-release/mynaric-receives-us-%2433-million-order-from-northrop-grumman-2023-12-13">getting a $33 million order</a>.</li>



<li>CISO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciso-stock-quote/">CISO</a>) shares are rising close to 15% on Wednesday morning.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is climbing over 14% <a href="https://finance.yahoo.com/news/carbon-revolution-provides-business-210500696.html">alongside a business update</a>.</li>



<li>Ault Alliance (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ault-stock-quote/">AULT</a>) shares are heading more than 14% higher after <a href="https://www.nasdaq.com/press-release/ault-alliance-reiterates-its-intention-to-commence-an-exchange-offer-of-common-stock">confirming plans for a share offering</a>.</li>



<li>LifeMD (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfmd-stock-quote/">LFMD</a>) stock is jumping over 13% after <a href="https://www.nasdaq.com/press-release/medifast-initiates-business-transformation-by-entering-the-medically-supported-weight">announcing a business transformation</a>.</li>



<li>C4 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cccc-stock-quote/">CCCC</a>) shares are up more than 12% as it <a href="CCCC">continues its recent rally</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Loop Media (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock is diving over 19% after <a href="https://www.nasdaq.com/press-release/loop-media-reports-full-year-2023-and-fourth-quarter-fiscal-financial-results-2023-12">missing its latest earnings estimates</a>.</li>



<li>Shengfeng Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfwl-stock-quote/">SFWL</a>) shares are tumbling more than 13% without any clear news this morning.</li>



<li>Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) stock is taking an over 12% beating on Wednesday morning.</li>



<li>Altisource Asset Management (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aamc-stock-quote/">AAMC</a>) shares are sliding more than 12% this morning.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock is dropping over 11% <a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-up-105-today/">following study news yesterday</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are decreasing nearly 11% on Wednesday morning.</li>



<li>Mobilicom (NASDAQ:<a href="https://investorplace.com/stock-quotes/mob-stock-quote/">MOB</a>) stock is falling almost 11% <a href="https://www.nasdaq.com/press-release/mobilicom-chosen-by-the-u.s.-department-of-defense-for-soldiers-next-generation">following a rally yesterday</a>.</li>



<li>Inpixon (NASDAQ:<a href="https://investorplace.com/stock-quotes/inpx-stock-quote/">INPX</a>) shares are declining more than 10% following <a href="https://www.nasdaq.com/press-release/inpixon-announces-shareholder-approval-of-proposals-related-to-merger-agreement-with">approval for a merger</a>.</li>



<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) stock is slipping over 9% this morning.</li>



<li>IN8bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/inab-stock-quote/">INAB</a>) shares close out our pre-market stock movers down close to 9% <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-dec-12th/">after rallying yesterday</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-dec-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ReShape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for <a href="https://finance.yahoo.com/news/reshape-lifesciences-receives-fda-pma-210500500.html">a PMA supplement</a>.



That a PMA supplement applies to the company&rsquo;s Lap-Band 2.0 FLEX. This is the company&rsquo;s minimally invasive, long-term treatment of obesity.



Paul Hickey, president and CEO of ReShape Lifesciences, explains the differences the come with its updated Lap-Band 2.0 FLEX product.




&ldquo;Compared to our current Lap-Band, the Lap-Band&reg; 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma.&rdquo;




<h2>What This Means for RSLS Stock</h2>



Improvement of its weight loss product is a positive for ReShape Lifesciences. The FDA approval also allows puts it closer to market, which could mean more revenue for the company.



With this news comes heavy trading of RSLS stock. As of this writing, around 50 million shares have changed hands. That&rsquo;s a massive leap in trading volume compared to the company&rsquo;s daily average of about 4 million shares.



RSLS stock is up 67.7% as of Wednesday morning.



There&rsquo;s more stock market news worth reading about below!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what&rsquo;s happening with shares of Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>), Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>)&nbsp;and Innovative International&nbsp;Acquisition&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock. You can find out more on these matters down below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Palantir Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock is in the news Wednesday after the big data company <a href="https://finance.yahoo.com/news/palantir-renews-digital-transformation-partnership-115900977.html">renewed a contract</a> with UniCredit.



According to a press release from Palantir, UniCredit has renewed its partnership with the company for another five years. That will see it make use of the Palantir Foundry operating system to enhance its digital transformation.



Investors will note that Palantir and UniCredit first started working together in 2018. Over those five years, UniCredit saw significant benefits from the Palantir Foundry operating system. That even resulted in it expanding the use of the technology to all CE&amp;EE UniCredit Legal Entities.



Josh Harris, a Palantir executive, said the following about this partnership.




&ldquo;Palantir has long been a proud partner to some of the world&rsquo;s top financial institutions. We&rsquo;re honored that UniCredit has placed its confidence in Palantir once again and look forward to furthering the bank&rsquo;s digital transformation.&rdquo;




<h2>PLTR Stock Movement on Wednesday</h2>



With this recent news comes some 7 million shares of PLTR stock changing hands. That&rsquo;s still a ways off from its daily average trading volume of about 61 million shares. The stock is also down 1.3% as of Wednesday morning despite the renewed contract. However, PLTR is up 170.4% year-to-date.



Investors looking for more of the latest stock market news will want to keep reading!



We have all of the hottest stock market news worth checking out on Wednesday! A few examples of that include what&rsquo;s happening with ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>), Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) and Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock. You can find more on these matters below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PLTR Stock: Palantir Renews UniCredit Partnership

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roblox (NYSE:<a href="https://investorplace.com/stock-quotes/rblx-stock-quote/">RBLX</a>) stock is on the move Wednesday as investors react to new coverage of the video game company&rsquo;s shares from Wells Fargo.



Wells Fargo analysts <a href="https://www.investing.com/news/stock-market-news/roblox-ads-to-become-significant-earnings-stream-over-time--wells-fargo-432SI-3255780">initiated coverage of RBLX stock</a> with an &ldquo;overweight&rdquo; rating. To put that in perspective, the analysts&rsquo; consensus rating for RBLX shares is moderate buy based on 22 opinions.



In addition to that, the company started its coverage of RBLX stock with a price target of $49 per share. That represents a potential upside of 16.6%. It&rsquo;s also bullish next to the analysts&rsquo; consensus price prediction of <a href="https://www.marketbeat.com/stocks/NYSE/RBLX/price-target/">$41.62 per share</a>.



<h2>Why the Bull Rating for RBLX Stock?</h2>



Here&rsquo;s what the Wells Fargo analysts had to say about Roblox in a note to clients obtained by Investing.com.




&ldquo;Similar to other audience platforms, we expect ads to become a significant earnings stream over time for Roblox, supported by strong user engagement. See meaningful upside to consensus bookings and EBITDA as we believe the ads opportunity is underappreciated by the Street, which has yet to properly capture future ad bookings into forecasts.&rdquo;




RBLX stock is up 2.5% as of Wednesday morning. This comes with more than 3.8 million shares traded. For the record, the company&rsquo;s daily average trading volume is still above that at 10.5 million shares.



Investors who want more of the latest stock market news are in luck!



We&rsquo;ve got all of the hottest stock market stories that traders need to know about on Wednesday! That includes everything going on with Palantir Technologies&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock, ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock and Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock. You can find out more on these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/rblx-stock-alert-wells-fargo-initiates-roblox-coverage-with-overweight-rating/">RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With &#8216;Overweight&#8217; Rating</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With 'Overweight' Rating

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Shattuck Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/sttk-stock-quote/">STTK</a>) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from <a href="https://finance.yahoo.com/news/shattuck-labs-announces-positive-initial-110000881.html">an ongoing Phase 1a/b trial</a>.



These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m Acute Myeloid Leukemia (AML) patients. Specifically, this focuses on initial data from a dose expansion announced earlier this year.



Dr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck Labs, said the following about this trial.




&ldquo;In dose escalation, we saw a monotherapy response to SL-172154 in a heavily pre-treated relapsed/refractory (R/R) TP53m AML patient that allowed the patient to receive a stem cell transplant. That patient remains disease free.&rdquo;




<h2>What&rsquo;s Next for STTK Stock?</h2>



If the company continues to see positive results from this clinical trial, more studies will likely follow. Investors are hoping for these as it puts Shattuck Labs closer to commercializing SL-172154. If that happens it could bring a new source of revenue to the company.



STTK stock is up 92.9% as of Wednesday morning with some 37 million shares changing hands. To put that in perspective, the company&rsquo;s daily average trading volume is closer to 56,000 shares.



There are even more stock market stories that traders will want to read about below!



We have all of the hottest stock happenings worth checking out on Wednesday! Among that is why shares of Roblox&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/rblx-stock-quote/">RBLX</a>), Palantir Technologies&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) and ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock are moving today. You can catch up on all of these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/rblx-stock-alert-wells-fargo-initiates-roblox-coverage-with-overweight-rating/">RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With &lsquo;Overweight&rsquo; Rating</a></li>



<li><a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-shattuck-labs-sttk-stock-up-93-today/">Why Is Shattuck Labs (STTK) Stock Up 93% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Shattuck Labs (STTK) Stock Up 93% Today?

Anti-obesity meds can expand the market for weight loss surgery: Bernstein

ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan

ReShape Lifesciences gets notice of allowance for additional U.S. patent

ReShape Lifesciences reports FY results

AAMC

AULT

CISO

CREV

EDSA

GMED

INPX

ISRG

KTTA

LFMD

NONOF

PLTR

RBLX

SFWL

VSME

Press Releases

Bariatric Surgery Devices Market Expected to Witness Massive Growth with a Tremendous CAGR of 5.22%, asserts DelveInsight | Companies – Standard Bariatrics, Inc., Apollo Endosurgery, J&J

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

Health Care

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update